Research Article

Intravenously Administered Human Umbilical Cord-Derived Mesenchymal Stem Cell (HucMSC) Improves Cardiac Performance following Infarction via Immune Modulation

Figure 2

Iv-administered HucMSC prevented adverse cardiac remodeling after MI. (a) Representative images of Masson’s trichrome staining and quantitative analysis of fibrosis percentage at 28 days after MI and HucMSC injection. Scale μm. (b) Heart weight (milligrams) to body weight (grams) ratio (HWI) at 28-day post-MI. (c) Representative images of WGA staining and quantitative analysis of cardiomyocyte CSA. Scale μm. (d) qRT-PCR measurement of ANP, BNP, and α-SMA at 28-day post-MI. (e) Representative images and quantitative analysis of CD31 staining at 28-day post-MI. Scale μm. WGA: wheat germ agglutinin; CSA: cross-sectional area.  ~ 6 mice for each group. vs. MI group.
(a)
(b)
(c)
(d)
(e)